XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues:        
Total revenues $ 784,395 $ 272,824 $ 983,469 $ 643,945
Operating expenses:        
Research and development 56,464,885 70,808,418 112,443,496 109,852,836
General and administrative 48,456,836 12,666,341 64,410,294 26,547,535
Total operating expenses 104,921,721 83,474,759 176,853,790 136,400,371
Loss from operations (104,137,326) (83,201,935) (175,870,321) (135,756,426)
Other income (expense):        
Interest income 857,667 928,111 1,527,481 1,697,347
Interest expense (313,488) (466,726) (626,976) (979,760)
(Loss) gain on investment in affiliated entities (934,015) 278,818 (1,471,743) (551,657)
Net unrealized (loss) gain on available-for-sale equity securities (3,967,101) 136,493 (8,807,742) (711,465)
Other (expense) income, net (3,048) 185,281 (156,516) 194,259
Net loss before share in net loss of Geneos (108,497,311) (82,139,958) (185,405,817) (136,107,702)
Share in net loss of Geneos 0 0 (2,165,213) (434,387)
Net loss $ (108,497,311) $ (82,139,958) $ (187,571,030) $ (136,542,089)
Net loss per share        
Basic (in dollars per share) $ (0.46) $ (0.39) $ (0.83) $ (0.66)
Diluted (in dollars per share) $ (0.46) $ (0.39) $ (0.83) $ (0.66)
Weighted average number of common shares outstanding        
Basic (in shares) 235,278,276 209,561,064 227,154,616 206,007,497
Diluted (in shares) 235,278,276 209,561,064 227,154,616 206,007,497
Revenue under collaborative research and development arrangements        
Revenues:        
Total revenues $ 36,839 $ 82,923 $ 102,734 $ 122,538
Revenue under collaborative research and development arrangements with affiliated entities        
Revenues:        
Total revenues 6,214 74,787 15,056 124,736
Other revenue        
Revenues:        
Total revenues $ 741,342 $ 115,114 $ 865,679 $ 396,671